MAFLD is defined as hepatic steatosis with metabolic dysregulation, type 2 diabetes mellitus, overweight or obesity, and is characterized by extensive liver lesions, which can progress from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, and even HCC
Metrics to track Beyond weight, track these metrics weekly or biweekly: Waist circumference at the navel, first thing in the morning Hip circumference at the widest point Energy level on a 1 to 10 scale Sleep quality on a 1 to 10 scale Appetite level on a 1 to 10 scale Side effects type and severity Exercise type and duration Request blood work from your provider at baseline, 12 weeks, and 24 weeks at minimum
2022) which requires the deactivation of tumour suppressor genes such as P53, RB and p16 (Dimri et al 2005) and/or activation of oncogenes
Schedule: TB-500 twice weekly (loading) then once weekly (maintenance)
Our approach to peptide therapy always starts with your unique biology and goals
